AbbVie Stock: What 10 Years of Growth and Dividends Did for $1,000

AbbVie built its empire on a single blockbuster drug, then watched biosimilars gut it almost overnight.

24/7 Wall Street • 6 hours ago

4 Reliable Dividend Stocks, Led by UPS, to Build Lifetime Passive Income

Wall Street spent years dismissing UPS as a broken dividend story, but a fresh earnings beat changed the conversation.

24/7 Wall Street • 11 hours ago

Best Dividend Aristocrats For November 2026

Dividend Aristocrats underperformed SPY in September but rebounded sharply in October, narrowing the YTD gap. NOBL and the average Aristocrat have YTD returns of 13.13% and 13.35%, trailing SPY's 14.15%. Dividend growth among Aristocrats accelerated, with the 2026 average increase now at 4.55%, bolstered by recent double-digit hikes.

Seeking Alpha • 17 hours ago

The Countdown Is On: BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Nov. 18

The holiday celebrates personalized treatment with BOTOX® Cosmetic across four FDA-approved aesthetic indication areas, the one and only of its kind in the United States.1 BOTOX® Cosmetic Day marks the biggest offer of the year for Allē Members. IRVINE, Calif.

PRNewsWire • Oct 28, 2026

Retire on Dividends: 5 High-Yield Stocks Boomers Are Buying and Holding Forever

Treasury yields near 5% make dividend stocks work harder to justify their risk, yet five companies spanning tobacco, pipelines, telecom, pharma, and net-lease real estate have kept raising their payouts through every rate spike in recent memory.

24/7 Wall Street • Oct 28, 2026

AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma

–  Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can potentially support treatment across a broad range of settings, including in community-based care –  In the Phase 3 CERVINO study, etentamig achieved statistically significant improvements in overall response rate (ORR) and progression-free survival (PFS) versus investigator's choice of standard available therapies –  Submission underscores AbbVie's ambition to advance a broad multiple myeloma portfolio that addresses disease complexity and supports patients' evolving care goals  NORTH CHICAGO, Ill., Oct. 27, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for etentamig, a second-generation BCMA x CD3 bispecific antibody T-cell engager administered intravenously for the treatment of adults with relapsed or refractory multiple myeloma.1 BCMA-directed bispecific antibodies and CAR-T therapies have significantly changed the treatment landscape for people living with multiple myeloma.2 However, their broader adoption may be limited by adverse events such as cytokine release syndrome, infections or neurotoxicity, as well as specialized administration and monitoring requirements.2,3,4 Additionally, as disease relapses, treatment options in later lines of therapy become increasingly limited.

PRNewsWire • Oct 27, 2026

Allergan Aesthetics Announces 2026 Grant Recipients of The Confidence Collective, Funded by BOTOX® Cosmetic (onabotulinumtoxinA)

Since its inception, The Confidence Collective has supported more than 500 women entrepreneurs and awarded more than $1.5 million in grants to fuel business growth and empower confidence. In 2026 alone, BOTOX® Cosmetic awarded 20 women entrepreneurs each with a $20,000 grant to help advance their business goals.

PRNewsWire • Oct 27, 2026

Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings

AbbVie heads into Q3 earnings with growth from Skyrizi and Rinvoq, but rising expenses, declining estimates and intensifying competition raise near-term concerns.

Zacks Investment Research • Oct 27, 2026

AbbVie: Analyzing Performance, Pipeline, And Pricing Ahead Of Q3 (Strong Buy)

AbbVie Inc. is trading at all-time highs, with robust 2026 guidance and a market cap exceeding $500bn. I expect ABBV Q3 earnings to outperform, driven by immunology assets Skyrizi and Rinvoq, which together will generate over $30bn in 2026. Despite an aging portfolio and pipeline concerns, ABBV's near-term growth and profit margins remain industry-leading, justifying a raised valuation target.

Seeking Alpha • Oct 27, 2026

What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?

Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q3'26 results.

Zacks Investment Research • Oct 27, 2026